RxDoctor Payments Data

Adrian Unger, APRN

Family · Tahlequah, OKNPI 1396210514

Payments from drug & device makers

$1,349in general payments, 2019–2025

Across 90 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$280
  • Neurocrine Biosciences, Inc.$193
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$176
  • Mylan Specialty L.p.$135
  • Vanda Pharmaceuticals Inc.$125
  • Lilly USA, LLC$112
  • plus $327 from 13 others

What the payments were for

  • Food & beverage$1,349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,349 in reported general payments places this provider in the 75th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$37,518
Medicare patients
102
Services billed
850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$103,711
MounjaroTirzepatide31$34,086
FarxigaDapagliflozin Propanediol24$19,233
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$16,835
JardianceEmpagliflozin11$12,854
JanuviaSitagliptin Phosphate17$10,943
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,549
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,632
Advair DiskusFluticasone Propion/Salmeterol11$3,010
Donepezil Hcl27$1,230
Ventolin HfaAlbuterol Sulfate20$1,110
Omeprazole87$1,103
Losartan Potassium120$1,102
Gabapentin65$1,101
Diclofenac Sodium41$819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$12$103,71197 claims
Lilly USA, LLCMounjaro$112$34,08631 claims
Boehringer IngelheimJardiance, Stiolto Respimat$44$18,48623 claims
GSKTrelegy Ellipta$21$16,83517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,026 family providers in Oklahoma.

Other family in Tahlequah

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →